Latest Bristol-Myers Squibb Stories
GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S.
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND
Editor Note: For more information about this release, please scroll to bottom. LONDON, May 21, 2014 /PRNewswire/ -- The markets on Tuesday, May 20, 2014 ended on
Supply of paclitaxel will not be disrupted for Canadian patients OTTAWA, May 9, 2014 /CNW/ - Health Canada today confirmed it has suspended the establishment licence of Biolyse
Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Anne Morisseau and Frank Spina of Bristol-Myers Squibb will speak at Pharmica’s
OTTAWA, May 6, 2014 /CNW/ - Health Canada today released the April 2014 issue of the Canadian Adverse Reaction Newsletter (CARN). This issue features an article on the risk
The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz.
LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
SAN DIEGO and TAIZHOU CITY, China, April 29, 2014 /PRNewswire/ -- Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd.
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 24, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts'